Replies to post #115414 on Biotech Values

[mcbio]

Seems a mighty expensive way to discover whether CRP is simply a biomarker reflecting existing inflammation (which is my mostly uninformed guess) or actually a bad actor in and of itself.

But if it's the latter they will have first-mover advantage in the clinic.

[jq1234]

CRP simply a biomarker reflecting existing inflammation

Accidentally I and a doctor discussed CRP biomarker today without knowing ISIS news. Both of us thought lowing CRP would less likely result much if any clinical benefit.

[RockRat]

There is some foundation for CRP being a bad actor rather than just a marker of bad acting . . .

http://www.medscape.com/viewarticle/542749

Considering this is from 2006, one wonders what happened to the molecule. Pentraxin Therapeutics has made much hype of the portfolio, but not much has gone anywhere. In the case of their CRP inhibitor, they suggested in '06 that trials might begin in a couple of year with adequate support . . .

More recently this:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662775/

That said, I hope they get proof of concept in less expensive indications first (which does seem to be the strategy) and then partner it or shelve it.

Regards, RockRat